

## NEW EVIDENCE ON MeMed BV'S ROLE IN SUPPORTING EMERGENCY MEDICINE CLINICAL DECISIONS UNVEILED AT ACEP 2025

**Saluggia, Italy - September 8, 2025** - Diasorin (FTSE MIB: DIA) announced today that several oral presentations at the upcoming American College of Emergency Physicians (ACEP) Scientific Assembly 2025 will showcase the growing body of clinical evidence supporting the utility of MeMed BV® in distinguishing between bacterial and viral infections based on the body's immune response.

The presentations span multiple leading U.S. medical centers and include real-world data, randomized controlled trial results, and new insights into MeMed BV's role in supporting clinical decisions with challenging patient populations, such as immunocompromised individuals and the elderly. Collectively, these studies underscore MeMed BV's potential to support decision-making in emergency departments (ED) and aid clinicians in their efforts to reduce unnecessary antibiotic use and unnecessary admissions, while lowering healthcare costs.

*"Emergency physicians face intense pressure to make rapid, high-stakes decisions with incomplete information,"* said Jason W. Wilson, MD, Emergency Medicine physician at Tampa General Hospital. *"Data emerging at ACEP suggest that MeMed BV could be a valuable tool for clinicians when guiding care — especially in complex scenarios like suspected sepsis patients, where clinical uncertainty is highest."*

### MeMed BV Data Presentations at ACEP 2025:

- Jason W. Wilson, MD, Tampa General Hospital - Preliminary data suggests that MeMed BV may provide clinical value to immunocompromised patients with suspected sepsis, a population where treatment decisions are particularly challenging.
- Alexandra LoVerde, Maimonides Medical Center - A real-world study demonstrates how MeMed BV may have potentially influenced antibiotic prescription and hospital admission decisions, leading to improved patient flow in the ED.
- Adam J. Singer, MD, Stony Brook University & Principal Investigator, JUNO Trial - Results from the JUNO randomized controlled trial show MeMed BV's role in supporting clinicians in their efforts to reduce antibiotic overuse, hospital admissions, and return visits, with potential cost savings of \$706 per patient.
- Adam J. Singer, MD, Stony Brook University - Additional analysis on elderly patients with suspected urinary tract infections, where MeMed BV provided clinicians with additional valuable information to support more accurate diagnosis and treatment decisions.

*"Growing evidence supports the clinical value of the LIAISON® MeMed BV® test in accurately distinguishing between bacterial and viral infections, empowering clinicians to make informed decisions that lead to more informed treatment decisions and improved patient outcomes",* commented Chen Even, Chief Commercial Officer of Diasorin.

**About Diasorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 31 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasorin.com](http://www.diasorin.com)

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:****INVESTOR RELATIONS****Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.com](mailto:riccardo.fava@diasorin.com)

**Eugenia Ragazzo**

Corporate Investor Relations & ESG Senior Analyst  
[eugenia.ragazzo@diasorin.com](mailto:eugenia.ragazzo@diasorin.com)